Session » Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy I: Safety of Biologics and Small Molecules in Rheumatoid Arthritis - Malignancy and Infection
-
Abstract Number: 844
Frequency of Significant Infection in Patients with RA Following Initiation of Rituximab with up to 5 Years of Follow-up in a US Observational Study
-
Abstract Number: 845
The Risk of Cancer with Tumor Necrosis Factor Inhibitors in Patients Concomitantly Exposed to Non-Biological Immunosuppressants Differs According to the Indication
-
Abstract Number: 846
Rheumatoid Arthritis, Anti-Tumor Necrosis Factor Therapy, and Risk of Squamous Cell and Basal Cell Skin Cancer- a Nationwide Population Based Prospective Cohort Study from Sweden
-
Abstract Number: 847
Safety of TNF Inhibitor Therapy in Patients Who Have Had a Prior Malignancy